DongKoo Bio&Pharma

DongKoo Bio&Pharma

Cho Yong-joon assumed control from his late father, Cho Dong-seop, building on a domestic manufacturing business that began with prescription medicine and cosmetics. Today the operating company runs three South Korean facilities — a Songpa-gu headquarters, an R&D center in Anyang, and a Hyangnam plant in Hwaseong — while Honorary Chairwoman Lee Kyung-ok, Cho’s mother, retains a presence in governance. The family’s wealth remains tightly linked to the underlying pharma business, which acts as both asset origin and ongoing income engine. Investment activity filters through a corporate balance sheet and a separate investment office at Parc.1 in Yeouido, Seoul’s financial district. The firm allocates across venture and growth equity, real estate, and private credit, with a sector bias toward healthcare services that mirrors its operating expertise. DongKoo participates directly in early-stage life-science startups through venture arms, and a Laos manufacturing joint venture with LVMC Holdings illustrates its willingness to deploy capital alongside operating partners where pharmaceutical production can scale regionally. The real-asset portfolio includes the investor-grade commercial building housing its own headquarters. Total investable assets are undisclosed; Altss estimates an allocation pool of roughly $150–$200 million derived from operating profits and real estate holdings. Chairman Cho also chairs the Korea Pharmaceutical Cooperative Association, placing the family at the center of domestic industry policy discussions — a role that shapes both operating strategy and the pipeline of deal flow reaching the investment office. DongKoo’s structural differentiator is the handshake distance between its manufacturing P&L and its investment committee. Unlike a general family office that liquidated an operating business, the firm runs a live CMO (contract manufacturing organization) whose revenues can absorb the illiquidity of early-stage biotech bets. This architecture gives Cho Yong-joon the ability to write patient, multi-year checks into Korean health-tech startups without relying on third-party fundraising cycles.